RT Journal Article
SR Electronic
T1 The rise of SARS-CoV-2 variant B.1.1.7 in Israel intensifies the role of surveillance and vaccination in elderly
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.16.21251819
DO 10.1101/2021.02.16.21251819
A1 Munitz, A
A1 Yechezkel, M
A1 Dickstein, Y
A1 Yamin, D.
A1 Gerlic, M
YR 2021
UL http://medrxiv.org/content/early/2021/02/19/2021.02.16.21251819.abstract
AB Since the emergence of the SARS-CoV-2 pandemic various generic variants have been described. Of specific interest is a new variant, which was observed in England during December 2020 and is now termed B.1.1.7. This variant is now associated with increased infectivity and therefore its spread within the community is of great importance. The Israeli government established three noteworthy programs namely, mass PCR testing, focused protection of the elderly and more recently an unparalleled prioritized vaccination program. In this study we analyzed primary data of >300,000 RT-PCR samples collected throughout December 6th 2020 until February 10th 2021 in the general community and nursing homes. We identified that within a period of six weeks, the B.1.1.7 variant was capable of out competing the wildtype SARS-CoV-2 strain to become the main strain. Furthermore, we show that the transmission of B.1.1.7 in the 60+ population reached a near complete halt, due to an ongoing surveillance testing program in nursing homes and the vaccination program of Israel. Thus, proactive protection programs such as routine surveillance and monitoring of populations at risk combined with prioritized vaccination, is achievable and will result in a reduction of severe illness and subsequent death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDY acknowledges funding from the European Research Council project #949850. The funders has no role in the design of the study, collection, analysis, and interpretation of data. MA acknowledges funding from the US-BSF grant #2011244, ISF grant #886/15, ICRF, and the Cancer Biology Research Center, Tel Aviv University. GM acknowledges funding from Alpha-1 foundation grant #615533 and US-BSF grant #2017176, ISF grant #818/18.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Tel Aviv University Institutional review board (IRB# 0002746-2).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request from the authors.